Research

Major differences in COVID patient care caused by insufficient data, misleading advice

While there was extensive use of drug repurposing throughout the first 10 months of the COVID-19 pandemic, there was substantial heterogeneity over the types of drugs used for treatment purposes globally. Some drugs, including hydroxychloroquine, saw sharp declines in use, while adjunctive therapies grew into a more relied upon method for patient management.

Researchers develop better way to determine safe drug doses for children

Determining safe yet effective drug dosages for children is an ongoing challenge for pharmaceutical companies and medical doctors alike. A new drug is usually first tested on adults, and results from these trials are used to select doses for pediatric trials. The underlying assumption is typically that children are like adults, just smaller, which often holds true, but may also overlook differences that arise from the fact that children's organs are still developing.

Our immune systems blanket the SARS-CoV-2 spike protein with antibodies

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, researchers at The University of Texas at Austin describe the finding, which represents good news for designing the next generation of vaccines to protect against variants of the virus or future emerging coronaviruses.

Using personalized medicine to avoid resistance to leukemia treatment

T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20. The standard treatment for T-ALL involves heavy chemotherapy procedures, which result in favorable outcomes with an overall survival of 75% after 5 years.

Speeding new treatments

A year into the COVID-19 pandemic, mass vaccinations have begun to raise the tantalizing prospect of herd immunity that eventually curtails or halts the spread of SARS-CoV-2. But what if herd immunity is never fully achieved - or if the mutating virus gives rise to hyper-virulent variants that diminish the benefits of vaccination?

Large collaboration creates cell atlas of COVID-19 pathology

Scientists from several hospitals and research centers have shown what happens in individual cells of patients who died of COVID-19. In a study published in Nature, the researchers describe how infected cells from multiple organs exhibited a range of molecular and genomic changes. They also saw signs of multiple, unsuccessful attempts by the lungs to repair themselves in response to respiratory failure, which is the leading cause of death in COVID-19 patients.

Brazilian coronavirus variant likely to be more transmissible and able to evade immunity

Even though more and more vaccines against the coronavirus are being administered all over the world, many countries are still battling with outbreaks and face difficulties providing help to those in need.

One of those countries is Brazil. Here, they are facing a massive second wave outbreak, many daily deaths and instances of the health care systems collapsing.

Major differences in COVID patient care caused by insufficient data, misleading advice

Researchers develop better way to determine safe drug doses for children

Our immune systems blanket the SARS-CoV-2 spike protein with antibodies

Using personalized medicine to avoid resistance to leukemia treatment

Speeding new treatments

Large collaboration creates cell atlas of COVID-19 pathology

Brazilian coronavirus variant likely to be more transmissible and able to evade immunity

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs